AT101

CAR-T treatment for hematologic cancer expressing the CD19

AT101 is a type of immunotherapy developed using CAR-T technology for the treatment of blood cancers expressing CD19

AbClon utilized the NEST discovery platform to derive a unique humanized antibody
(compared to conventional antibodies targeting the FMC63 site of CD19). Our antibody
with its unique mode of action demonstrates stronger therapeutic effects compared to
existing CAR-T treatments and represents a new hope for patients who do not respond
to current FMC63-based CAR-T treatments.